Post-Market Surveillance & PSUR
PMS obligations overview
All device classes in Saudi Arabia must maintain active Post-Market Surveillance (PMS) — systematically collecting and analysing data from marketed devices. The outputs differ by class:
| Class | Required report | Update frequency |
|---|---|---|
| Class A | PMS Report | As needed; available on SFDA request |
| Class B | Periodic Safety Update Report (PSUR) | At least every 2 years |
| Class C | PSUR | Annually |
| Class D | PSUR | Annually |
Class A — PMS Report
The PMS Report for Class A devices must include:
- Summary of PMS data collected (complaints, adverse events, literature data)
- Analysis findings and conclusions
- Any CAPAs taken as a result
The PMS Report is maintained internally and must be made available to the SFDA on request.
Class B, C, D — PSUR
The Periodic Safety Update Report (PSUR) is a more comprehensive document including:
- Full PMS data summary
- Risk-benefit determination conclusions — updated assessment of overall device risk-benefit
- PMCF results — data from post-market clinical follow-up studies
- Sales volume data — to contextualise the rate of adverse events
- Analysis of any new safety signals
- Summary of any FSCAs or recalls in the reporting period
- Updated CAPA records
Class B manufacturers must update the PSUR at least every two years; Class C and D manufacturers must update annually.
PMS data sources
PMS data should be gathered from multiple sources:
- Complaints and adverse event reports received
- NCMDR feedback and communications
- Published scientific literature (systematic review)
- PMCF study data
- Data from equivalent devices on other markets
- Incident databases from IMDRF member regulators
PMCF (Post-Market Clinical Follow-up)
PMCF is the structured, ongoing collection of clinical data for devices already on the market. For Class C and D devices, the SFDA expects an active PMCF programme. PMCF data feeds into the PSUR and the CER at renewal.
Further reading
- MDS-REQ 5 — PMS and vigilance requirements
- MDS-REQ 4 — Clinical Evaluation (PMCF component)
- Adverse Event Reporting
- MDMA Renewal